CLASSICAL HODGKIN LYMPHOMA
Clinical trials for CLASSICAL HODGKIN LYMPHOMA explained in plain language.
Never miss a new study
Get alerted when new CLASSICAL HODGKIN LYMPHOMA trials appear
Sign up with your email to follow new studies for CLASSICAL HODGKIN LYMPHOMA, keep track of the ones that matter, and come back to a personal dashboard instead of checking manually.
By submitting, you agree to our Terms of use
-
New strategy aims to stop Cancer's return after transplant
Disease control CompletedThis study tested whether giving a drug called brentuximab vedotin for up to one year after a stem cell transplant could help prevent Hodgkin lymphoma from coming back. The treatment was given to 14 adults whose cancer had returned or hadn't responded to previous treatments. Rese…
Matched conditions: CLASSICAL HODGKIN LYMPHOMA
Phase: PHASE2 • Sponsor: University of Cologne • Aim: Disease control
Last updated Apr 01, 2026 14:42 UTC
-
New drug shows promise against Tough-to-Treat blood cancer
Disease control CompletedThis study tested an immunotherapy drug called tislelizumab in 46 people whose classical Hodgkin lymphoma had come back or stopped responding to prior treatments. The main goal was to see how many patients' tumors shrank or disappeared after receiving the drug. Participants recei…
Matched conditions: CLASSICAL HODGKIN LYMPHOMA
Phase: PHASE2 • Sponsor: BeiGene • Aim: Disease control
Last updated Mar 30, 2026 14:29 UTC
-
Blood test could predict hodgkin lymphoma relapse
Knowledge-focused CompletedThis study tested if a specific genetic change (XPO1 E571K mutation) found in the blood could be used to monitor patients with classical Hodgkin lymphoma. Researchers followed 137 adults with newly diagnosed Hodgkin lymphoma to see if detecting this mutation in blood tests could …
Matched conditions: CLASSICAL HODGKIN LYMPHOMA
Phase: NA • Sponsor: Centre Henri Becquerel • Aim: Knowledge-focused
Last updated Mar 30, 2026 14:32 UTC